Physician survey of the effect of the 21-gene recurrence score assay results on treatment recommendations for patients with lymph node-positive, estrogen receptor-positive breast cancer.
about
Clinicians' expectations for gene-driven cancer therapyPredictive and prognostic value of the 21-gene recurrence score in hormone receptor-positive, node-positive breast cancer.Emerging gene-based prognostic tools in early breast cancer: First steps to personalised medicine.Prospective Clinical Utility Study of the Use of the 21-Gene Assay in Adjuvant Clinical Decision Making in Women With Estrogen Receptor-Positive Early Invasive Breast Cancer: Results From the SWITCH StudyBarriers to the use of personalized medicine in breast cancer.Psychosocial and Quality of Life in Women Receiving the 21-Gene Recurrence Score Assay: The Impact of Decision Style in Women with Intermediate RS.Effect of 21-Gene RT-PCR Assay on Adjuvant Therapy and Outcomes in Patients With Stage I Breast CancerCost effectiveness of personalized treatment in women with early breast cancer: the application of OncotypeDX and Adjuvant! Online to guide adjuvant chemotherapy in Austria.The value of multigene predictors of clinical outcome in breast cancer: an analysis of the evidenceUnderstanding how breast cancer patients use risk information from genomic tests.The 21-gene recurrence score assay impacts adjuvant therapy recommendations for ER-positive, node-negative and node-positive early breast cancer resulting in a risk-adapted change in chemotherapy use.The impact of the 21-gene Recurrence Score assay on clinical decision-making in node-positive (up to 3 positive nodes) estrogen receptor-positive breast cancer patients.TOP2A RNA expression and recurrence in estrogen receptor-positive breast cancer.Is There a Role for Oncotype Dx Testing in Invasive Lobular Carcinoma?Treatment decisions in estrogen receptor-positive early breast cancer patients with intermediate oncotype DX recurrence score results.Physicians' attitudes about multiplex tumor genomic testing.The application of Oncotype DX in early-stage lymph-node-positive disease.Diagnostic tests based on gene expression profile in breast cancer: from background to clinical use.Associations between use of the 21-gene recurrence score assay and chemotherapy regimen selection in a statewide registry.The impact of genomic testing on the recommendation for radiation therapy in patients with ductal carcinoma in situ: A prospective clinical utility assessment of the 12-gene DCIS score™ result.Economic impact of 21-gene recurrence score testing on early-stage breast cancer in Ireland.Prospective Evaluation of the Impact of the 21-Gene Recurrence Score Assay on Adjuvant Treatment Decisions for Women with Node-Positive Breast Cancer in Ontario, Canada.Clinical and economic impact of the 21-gene recurrence score assay in adjuvant therapy decision making in patients with early-stage breast cancer: pooled analysis in 4 Basque Country university hospitals.Comparison of Oncotype DX® Recurrence Score® with other risk assessment tools including the Nottingham Prognostic Index in the identification of patients with low-risk invasive breast cancer.Impact of Oncotype DX testing on adjuvant treatment decisions in patients with early breast cancer: a single-center study in the United Arab Emirates.
P2860
Q28083844-B8710731-CD74-4AB6-8BF0-742698EBF7A6Q34171119-9001FDE5-8330-4B11-96B7-FED99DB94388Q34657656-010139DE-8F67-448B-A636-67A5C8E2F69FQ35915708-6B05A290-EADE-4345-8E6E-D55918113B78Q36095254-24213535-C462-49BC-A1C7-7505416C9457Q36147839-A03B0321-7BC0-4CC1-8379-E22E9D03AC12Q36279583-18828CA0-278B-499D-81E3-A01EF0E0A684Q36339076-F7AA4EC4-4F17-45A2-B5E6-ADB52143C984Q36462893-FC4BFF21-EE00-4D50-8A5D-711FB9450D4BQ36503688-9A4071C2-ABB4-4910-8D8D-52B03E784115Q36615770-AE054163-C310-4F17-A077-15FFF378363CQ36997719-DB33EB21-994D-4992-9D32-48DAB42C646EQ37136305-3D3F3E57-C28A-41F7-B309-9BF7D78AE300Q37199779-195FABF5-1718-4135-AC87-74A76B95268BQ37586558-8761E77F-2DE4-4452-B0C6-61E0135082C9Q37712065-D9F1B228-1FB4-4E40-9A65-5AF40CF04110Q38180001-1784BA80-D0D6-4363-9096-29B15625906AQ38232507-043652F3-E211-4E5D-91CF-4F024F0BD994Q39243861-800F5329-772A-4E77-826F-2AE2A53043E9Q40882141-5164B55E-F0E7-4B90-87F7-1123E03C5870Q41367403-2D578FDF-9D29-4FF4-9C67-DD20307D70D8Q48163403-7986BDEB-76C9-4323-A243-6F68B9EC125BQ51733186-56B96ABA-A402-4D3C-89E2-C9942F21319FQ51827185-12732E50-57D2-4E9B-865C-48EC7383E1B8Q54191141-964A6466-077D-4FEC-9946-F572A3CD65F1
P2860
Physician survey of the effect of the 21-gene recurrence score assay results on treatment recommendations for patients with lymph node-positive, estrogen receptor-positive breast cancer.
description
2011 nî lūn-bûn
@nan
2011 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մարտին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Physician survey of the effect ...... ceptor-positive breast cancer.
@ast
Physician survey of the effect ...... ceptor-positive breast cancer.
@en
Physician survey of the effect ...... ceptor-positive breast cancer.
@nl
type
label
Physician survey of the effect ...... ceptor-positive breast cancer.
@ast
Physician survey of the effect ...... ceptor-positive breast cancer.
@en
Physician survey of the effect ...... ceptor-positive breast cancer.
@nl
prefLabel
Physician survey of the effect ...... ceptor-positive breast cancer.
@ast
Physician survey of the effect ...... ceptor-positive breast cancer.
@en
Physician survey of the effect ...... ceptor-positive breast cancer.
@nl
P2093
P2860
P356
P1476
Physician survey of the effect ...... ceptor-positive breast cancer.
@en
P2093
Benjamin Kim
Calvin Chao
Michael Broder
Roberto Bugarini
Ruth Oratz
Stanley Skrzypczak
P2860
P356
10.1200/JOP.2010.000046
P407
P577
2011-03-01T00:00:00Z